Unusual 11 Mid-Day Movers 03/12: (TUDO) (PCBC) (JVA) Higher; (ANTH) (TZYM) (DYN) Lower
Tweet
Share
E-mail
Get Alerts TUDO Hot Sheet
Join SI Premium – FREE
Tudou Holdings Limited (Nasdaq: TUDO) 146.4% HIGHER; Youku and Tudou entered an agreement whereby Youku will acquire Tudou for 1.595 Youku ADS per Tudou Class A share, or about $1 billion in total.
Pacific Capital Bancorp (Nasdaq: PCBC) 57.0% HIGHER; UnionBanCal Corporation entered into a definitive agreement to acquire Pacific Capital for $46 per share in cash.
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) 46.3% LOWER; reported last Friday that the VISTA-16 Data Safety Monitoring Board (DSMB) has recommended stopping the VISTA-16 clinical study due to a lack efficacy that could not be reasonably overcome in the remainder of the trial. The DSMB's recommendation was based on a review of the totality of the safety and efficacy data available for the VISTA-16 clinical study. Shares were downgraded by Cowen and Citi Monday.
Tranzyme Pharma (Nasdaq: TZYM) 42.2% LOWER; Tranzyme and Norgine B.V. today announced top-line results of the primary analysis of ULISES 007, the first of two Phase 3 pivotal trials evaluating ulimorelin. The trial failed to meet its primary and secondary efficacy endpoints. For more color, click here.
Coffee Holding Co. (Nasdaq: JVA) 27.8% HIGHER; CEO Andrew Gordon presented at the 24th Annual Roth Investor Conference today. To view the presentation, click here.
Youku Inc. (NYSE: YOKU) 23.6% HIGHER; see Tudou above.
ZOLL Medical Corporation (Nasdaq: ZOLL) 23.6% HIGHER; Asahi Kasei Corporation and ZOLL Medical jointly announced that Asahi Kasei, Japan’s leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, has entered into a definitive merger agreement with ZOLL, a manufacturer of resuscitation and critical care devices and related software solutions, pursuant to which Asahi Kasei will acquire ZOLL for approximately $2.21 billion. The transaction has been approved by the Boards of Directors of both companies.
Dynegy (NYSE: DYN) 17.3% LOWER; BTIG downgraded Dynegy from Buy to Neutral. For more color, click here.
Velti plc (Nasdaq: VELT) 17.2% HIGHER; reported Q4 EPS of $0.59, $0.11 better than the analyst estimate of $0.48. Revenue for the quarter came in at $87.1 million versus the consensus estimate of $81.83 million. The company sees Q1 2012 revenue of $44-$48 million, versus the consensus of $44.97 million. Velti also sees FY2012 revenue of $280-$295 million, versus the consensus of $280.98 million.
Verso Paper Corp. (NYSE: VRS) 15.2% LOWER; after moving 21 percent higher last Friday, Verso is seeing some profit taking Monday. Shares are still up about 73 percent since last Wednesday.
Lime Energy Co. (Nasdaq: LIME) 7.8%LOWER; Lime is continuing lower Monday following a 6.5 percent drop last Friday on its quarterly numbers.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Pacific Capital Bancorp (Nasdaq: PCBC) 57.0% HIGHER; UnionBanCal Corporation entered into a definitive agreement to acquire Pacific Capital for $46 per share in cash.
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) 46.3% LOWER; reported last Friday that the VISTA-16 Data Safety Monitoring Board (DSMB) has recommended stopping the VISTA-16 clinical study due to a lack efficacy that could not be reasonably overcome in the remainder of the trial. The DSMB's recommendation was based on a review of the totality of the safety and efficacy data available for the VISTA-16 clinical study. Shares were downgraded by Cowen and Citi Monday.
Tranzyme Pharma (Nasdaq: TZYM) 42.2% LOWER; Tranzyme and Norgine B.V. today announced top-line results of the primary analysis of ULISES 007, the first of two Phase 3 pivotal trials evaluating ulimorelin. The trial failed to meet its primary and secondary efficacy endpoints. For more color, click here.
Coffee Holding Co. (Nasdaq: JVA) 27.8% HIGHER; CEO Andrew Gordon presented at the 24th Annual Roth Investor Conference today. To view the presentation, click here.
Youku Inc. (NYSE: YOKU) 23.6% HIGHER; see Tudou above.
ZOLL Medical Corporation (Nasdaq: ZOLL) 23.6% HIGHER; Asahi Kasei Corporation and ZOLL Medical jointly announced that Asahi Kasei, Japan’s leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, has entered into a definitive merger agreement with ZOLL, a manufacturer of resuscitation and critical care devices and related software solutions, pursuant to which Asahi Kasei will acquire ZOLL for approximately $2.21 billion. The transaction has been approved by the Boards of Directors of both companies.
Dynegy (NYSE: DYN) 17.3% LOWER; BTIG downgraded Dynegy from Buy to Neutral. For more color, click here.
Velti plc (Nasdaq: VELT) 17.2% HIGHER; reported Q4 EPS of $0.59, $0.11 better than the analyst estimate of $0.48. Revenue for the quarter came in at $87.1 million versus the consensus estimate of $81.83 million. The company sees Q1 2012 revenue of $44-$48 million, versus the consensus of $44.97 million. Velti also sees FY2012 revenue of $280-$295 million, versus the consensus of $280.98 million.
Verso Paper Corp. (NYSE: VRS) 15.2% LOWER; after moving 21 percent higher last Friday, Verso is seeing some profit taking Monday. Shares are still up about 73 percent since last Wednesday.
Lime Energy Co. (Nasdaq: LIME) 7.8%LOWER; Lime is continuing lower Monday following a 6.5 percent drop last Friday on its quarterly numbers.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Traders push back timing of first rate cut to December
- TD Cowen Reiterates Buy Rating on Seagate Technology (STX)
- TD Cowen Reiterates Buy Rating on Edwards Lifesciences (EW)
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Citi, Cowen & Co, Unusual 11 Mid-Day MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
